HRP20191348T1 - Aminosteroidi za liječenje bolesti povezanih s ptp1b - Google Patents

Aminosteroidi za liječenje bolesti povezanih s ptp1b Download PDF

Info

Publication number
HRP20191348T1
HRP20191348T1 HRP20191348TT HRP20191348T HRP20191348T1 HR P20191348 T1 HRP20191348 T1 HR P20191348T1 HR P20191348T T HRP20191348T T HR P20191348TT HR P20191348 T HRP20191348 T HR P20191348T HR P20191348 T1 HRP20191348 T1 HR P20191348T1
Authority
HR
Croatia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
treatment
tyrosine
Prior art date
Application number
HRP20191348TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael Mclane
Inez Ruiz-White
W. Lee Maloy
Henry R. Wolfe
Original Assignee
Ohr Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohr Pharmaceutical, Inc. filed Critical Ohr Pharmaceutical, Inc.
Publication of HRP20191348T1 publication Critical patent/HRP20191348T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20191348TT 2012-04-20 2013-04-19 Aminosteroidi za liječenje bolesti povezanih s ptp1b HRP20191348T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636252P 2012-04-20 2012-04-20
PCT/US2013/037330 WO2013158970A2 (en) 2012-04-20 2013-04-19 Aminosteroids for the treatment of a ptp1b associated disease
EP13721176.9A EP2838907B1 (en) 2012-04-20 2013-04-19 Aminosteroids for the treatment of a ptp1b associated disease

Publications (1)

Publication Number Publication Date
HRP20191348T1 true HRP20191348T1 (hr) 2019-10-18

Family

ID=48325893

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191348TT HRP20191348T1 (hr) 2012-04-20 2013-04-19 Aminosteroidi za liječenje bolesti povezanih s ptp1b

Country Status (15)

Country Link
US (6) US9546194B2 (https=)
EP (2) EP2838907B1 (https=)
JP (4) JP6165843B2 (https=)
KR (3) KR101963312B1 (https=)
AU (3) AU2013249111B2 (https=)
CA (1) CA2870671C (https=)
DK (1) DK2838907T3 (https=)
ES (1) ES2736310T3 (https=)
HR (1) HRP20191348T1 (https=)
HU (1) HUE044769T2 (https=)
MX (2) MX367255B (https=)
PL (1) PL2838907T3 (https=)
PT (1) PT2838907T (https=)
TR (1) TR201911039T4 (https=)
WO (1) WO2013158970A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2736310T3 (es) * 2012-04-20 2019-12-27 Ohr Pharmaceutical Inc Aminoesteroides para el tratamiento de una enfermedad asociada a PTP1B
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
MA50094A (fr) * 2017-09-08 2020-07-15 Enterin Inc Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
CN107802626B (zh) * 2017-10-11 2020-01-21 南昌大学 降血糖组合物及其制备方法、用途
CN111801102B (zh) * 2017-11-06 2024-05-28 冷泉港实验室 用于形成含铜络合物的方法和组合物及其用途
KR20200146038A (ko) * 2018-03-27 2020-12-31 엔테린, 인코포레이티드 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물
AU2019308311B2 (en) * 2018-07-20 2024-12-05 Cold Spring Harbor Laboratory (pyridinylmethyl)butanediamine derivatives that chelate copper
WO2021025974A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same
EP4007764B1 (en) * 2019-08-02 2026-01-21 Enterin, Inc. Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
WO2023230593A1 (en) 2022-05-27 2023-11-30 Cold Spring Harbor Laboratory Ptp1b inhibitors for treating lung injury

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403683A (en) * 1942-04-25 1946-07-09 Relchstein Tadeus Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same
US3636210A (en) * 1968-02-02 1972-01-18 Merck & Co Inc Cholanic acid and cholenic acid compositions and method of treatment
IT1255450B (it) * 1992-06-30 1995-10-31 Montefarmaco Spa Uso di acidi biliari come agenti antivirali
WO1994019366A1 (en) * 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
DE69412596T2 (de) * 1993-03-10 1999-03-04 Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
ATE259375T1 (de) * 1995-06-07 2004-02-15 Genaera Corp Aminosterinverbindungen als inhibitoren der natrium/proton-pump, pharmazeutische methoden und präparaten davon
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
EP1214060A2 (en) 1999-09-10 2002-06-19 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
AU6985300A (en) 1999-09-10 2001-04-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
JP2003509429A (ja) 1999-09-10 2003-03-11 ノボ ノルディスク アクティーゼルスカブ タンパク質チロシンホスファターゼ(ptpアーゼ)のモジュレーター
WO2001042273A2 (en) 1999-12-09 2001-06-14 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU2003292939A1 (en) * 2002-12-24 2004-07-22 The University Of British Columbia Angiogenic compounds and uses thereof
JP2006165843A (ja) * 2004-12-06 2006-06-22 Matsushita Electric Ind Co Ltd 画像処理装置
US20080058300A1 (en) * 2006-04-21 2008-03-06 Mclane Michael Induction of weight loss and the selective inhibition of PTP1B
JP2010538072A (ja) * 2007-09-06 2010-12-09 ジェナエラ コーポレイション 糖尿病を治療する方法
KR101260221B1 (ko) * 2011-12-01 2013-05-06 주식회사 엘지화학 마스크
ES2736310T3 (es) * 2012-04-20 2019-12-27 Ohr Pharmaceutical Inc Aminoesteroides para el tratamiento de una enfermedad asociada a PTP1B

Also Published As

Publication number Publication date
KR101963312B1 (ko) 2019-03-28
JP2021073250A (ja) 2021-05-13
MX2014012619A (es) 2015-01-15
AU2020203736A1 (en) 2020-06-25
AU2013249111B2 (en) 2018-08-09
TR201911039T4 (tr) 2019-08-21
JP6165843B2 (ja) 2017-07-19
US20230203088A1 (en) 2023-06-29
DK2838907T3 (da) 2019-08-05
US9546194B2 (en) 2017-01-17
JP2015514781A (ja) 2015-05-21
MX2019009539A (es) 2019-09-26
EP3556765A1 (en) 2019-10-23
AU2018256561B2 (en) 2020-03-05
EP2838907A2 (en) 2015-02-25
US20190202858A1 (en) 2019-07-04
EP2838907B1 (en) 2019-05-22
KR102057812B1 (ko) 2019-12-19
US20250002525A1 (en) 2025-01-02
US20170129914A1 (en) 2017-05-11
WO2013158970A2 (en) 2013-10-24
HK1205516A1 (en) 2015-12-18
KR20150003798A (ko) 2015-01-09
US10556923B2 (en) 2020-02-11
AU2020203736B2 (en) 2021-12-02
PL2838907T3 (pl) 2019-12-31
AU2018256561A1 (en) 2018-11-22
MX367255B (es) 2019-08-12
US20200270300A1 (en) 2020-08-27
HUE044769T2 (hu) 2019-11-28
JP6457010B2 (ja) 2019-01-23
JP2019059781A (ja) 2019-04-18
CA2870671C (en) 2020-05-12
KR20190034685A (ko) 2019-04-02
CA2870671A1 (en) 2013-10-24
US11434257B2 (en) 2022-09-06
JP2017178951A (ja) 2017-10-05
US20150099727A1 (en) 2015-04-09
EP3556765B1 (en) 2022-02-23
WO2013158970A3 (en) 2013-12-12
AU2013249111A1 (en) 2014-11-06
PT2838907T (pt) 2019-08-05
ES2736310T3 (es) 2019-12-27
KR20160091435A (ko) 2016-08-02

Similar Documents

Publication Publication Date Title
HRP20191348T1 (hr) Aminosteroidi za liječenje bolesti povezanih s ptp1b
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
EP2753348A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
JP2012107034A5 (https=)
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
HUE053946T2 (hu) 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére
EP2720743A4 (en) MASK FOR THE ADMINISTRATION OF A MEDICAMENT TO BE TAKEN
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
PL3604536T3 (pl) Modulujące rna oligonukleotydy o ulepszonych właściwościach do leczenia zaburzeń nerwowo-mięśniowych
ME02910B (me) Spojevi tetrahidropirolotiazina
EP2841092A4 (en) METHODS, COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARAIN FLUENZA VIRUS IN IMMUNE-GROWTH PATIENTS
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
EP2814486A4 (en) ANTIVIRAL AGENT FOR THE TREATMENT OF ARENAVIRUS INFECTIONS
EP2678007A4 (en) PROTEIN NANOTRIER FOR TOPICAL ADMINISTRATION
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
HUE040231T2 (hu) Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére
GT201400161A (es) Fenilimidazopirazoles sustituidos y su uso
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
JP2013523758A5 (https=)
SMT201600334B (it) Interferone beta per l'uso nel trattamento della malattia del tratto respiratorio inferiore causata da influenza
EP2793933A4 (en) TREATMENT OF COGNITIVE INTERFERENCE BY HUNTER SYNDROME BY INTRATHEKAL ADMINISTRATION OF IDURONATE-2-SULFATASE
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti
FR2993564B1 (fr) Derives d'imidazopyridine utiles dans le traitement du diabete